BGI Group and Illumina units settle US DNA sequencing lawsuits

The offices of genetic sequencing company Illumina Inc are shown in San Diego. REUTERS/Mike Blake

Join now for FREE unlimited access to Reuters.com

Register

  • Illumina said it would pay $325 million to resolve US court cases
  • Rivals agree not to file U.S. patent and antitrust lawsuits for three years

(Reuters) – Illumina Inc and MGI Tech Co and BGI Group’s Complete Genomics have settled U.S. litigation over their rival DNA sequencing technology, the companies said on Thursday.

Illumina agreed to pay $325 million to end US litigation, they said, following recent jury verdicts in patent cases in California and Delaware. The settlement also resolves an ongoing antitrust lawsuit brought by BGI affiliates against Illumina in California.

An MGI Release and an Illumina filing with the United States Securities and Exchange Commission said Illumina would be licensed for patents from BGI subsidiaries and the companies would not sue for patent infringement or antitrust in the United States. over the next three years.

Join now for FREE unlimited access to Reuters.com

Register

MGI declined to comment further. Illumina and one of its attorneys did not immediately respond to a request for comment.

Complete Genomics is a US subsidiary of MGI, which is a subsidiary of BGI Group. He and San Diego-based Illumina are the two main providers of genome analysis technology used to detect genetic diseases.

The companies have been embroiled in a global legal battle over their respective sequencing technologies, with lawsuits in countries including Germany, Denmark, Switzerland and Turkey. Thursday’s settlement announcement refers only to US cases.

A Delaware jury awarded Complete Genomics $333 million in May after it found that Illumina’s “two-channel” sequencing systems and kits for preparing DNA fragments for sequencing violated its patent rights.

Illumina previously won $8 million and a temporary ban on US sales of certain BGI Group sequencers based on its own patent claims in federal court in San Francisco.

The cases are Complete Genomics Inc v. Illumina Inc, US District Court for the District of Delaware, No. 1:19-cv-00970; Complete Genomics Inc v. Illumina Inc, US District Court for the Northern District of California, No. 3:21-cv-00217; and Illumina Inc v. BGI Genomics Co Ltd, US District Court for the Northern District of California, No. 3:20-cv-01465.

For BGI Affiliates: David Bilsker of Quinn Emanuel Urquhart & Sullivan

For Illumina: Edward Reines by Weil Gotshal & Manges

Read more:

Illumina ordered to pay $333 million to BGI subsidiary in DNA sequencing patent case

Illumina Wins Extended US Ban on BGI Gene Sequencer Sales

BGI and Illumina antitrust dispute suspended over patent case

Join now for FREE unlimited access to Reuters.com

Register

Our standards: The Thomson Reuters Trust Principles.

About Jessica J. Bass

Check Also

BMW Group Takes Inclusive Communications to the Next Level by Announcing the Artificial Intelligence Challenge

Last week saw the launch of the “Joyful Diversity with AI” challenge, focusing …